NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

肝素市場成長機會·成長預測 (2021-2028年):產品 (未分級肝素·低分子量肝素·超低分子量肝素)·用途·通路·各地區

Heparin Market by Product (Unfractionated Heparin, Low Molecular Weight Heparin, and Ultra-Low Molecular Weight Heparin ), Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2028

出版商 Allied Market Research 商品編碼 1017248
出版日期 內容資訊 英文 221 Pages
商品交期: 2-3個工作天內
價格
肝素市場成長機會·成長預測 (2021-2028年):產品 (未分級肝素·低分子量肝素·超低分子量肝素)·用途·通路·各地區 Heparin Market by Product (Unfractionated Heparin, Low Molecular Weight Heparin, and Ultra-Low Molecular Weight Heparin ), Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2028
出版日期: 2021年05月21日內容資訊: 英文 221 Pages
簡介

全球肝素的市場規模在預測期間內預計將以6.6%的年複合成長率推移,從2020年的65億3500萬美元,到2028年達到110億1500萬美元的規模。

由於包括心血管疾病在內的各種因素,靜脈血栓形成的發病率不斷增加,正在推動市場的增長。肝素還用於骨科和心臟手術等手術,因此手術數量的增加正在推動市場增長。血小板減少症、安全性和供應挑戰等副作用是市場增長的障礙,但合成和半合成肝素的可用性增加,政府資金增加以改善醫療設施。大規模研發活動以開發具有高治療效果和副作用少,有望為市場帶來利好機會。

本報告提供全球肝素的市場調查,彙整市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,專利趨勢,市場規模的轉變·預測,產品·用途·通路·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義·範圍
  • 主要調查結果
  • 波特分析
  • 主要企業的地位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19:影響分析

第4章 市場分析·預測:各產品

  • 未分級肝素
  • 低分子量肝素(LMWH)
  • 超低分子量肝素(ULMWH)
    • 主要趨勢·成長要素·成長機會
    • 市場規模·預測
    • 市場分析:各國

第5章 市場分析·預測:各用途

  • 靜脈血栓栓塞症
  • 冠狀動脈疾病
  • 心房纖維顫動
  • 其他
    • 市場規模·預測
    • 市場分析:各國

第6章 市場分析·預測:各銷售管道

  • 醫院藥局
  • 藥妝店·零售藥局
  • 線上藥局
    • 市場規模·預測:各地區
    • 市場分析:各國

第7章 市場分析·預測:地區·各主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲
    • 主要趨勢·成長要素·成長機會
    • 市場規模·預測:各國
    • 市場分析·預測:各產品
    • 市場分析·預測:各用途
    • 市場分析·預測:各銷售管道

第8章 企業簡介

  • Baxter International Inc.
  • B. Braun Holding GmbH & Co. KG
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co KGaA
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
  • Leo Pharma A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • Viatris Inc.
目錄
Product Code: A06186

The global heparin market was valued at $6,535 million in 2020, and is projected to reach $11,015 million by 2028, registering a CAGR of 6.6% from 2021 to 2028.

Heparin is an anticoagulant medication and a naturally occurring glycosaminoglycan produced by basophils and mast cells in all mammals. It is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. It is used in the treatment of various health conditions, such as acute coronary syndrome, deep-vein thrombosis, pulmonary embolism, atrial fibrillation, and is also used during heart surgery for carrying out cardiopulmonary bypass as well as hemofiltration. It is also administered for major orthopedic surgeries such as hip replacement and knee replacement. Recent development in heparin research to develop heparin with ultra-low molecular weight for utilization in chemotherapy opened new avenues for the heparin market.

Rise in occurrence of venous thrombosis due to various underlying factors, such as cardiovascular diseases, drive the growth of the global heparin market. In addition, application of heparin in various surgeries, such as orthopedic and heart surgeries, and increase in number of patients undergoing such surgeries further boost the growth of the market. However, many adverse side-effects associated with heparin, such as heparin-induced thrombocytopenia, restrain the growth of the market. In addition, as heparin is derived from animal sources, it poses a significant safety and supply issue, which further limits the growth of the market. In contrast, availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation, and inflammatory diseases is anticipated to provide lucrative opportunities for the adoption of heparin products. Moreover, increase in government funding toward improving healthcare facilities and extensive R&D activities to develop heparin with improved therapeutic potential and minimal side-effects are anticipated to further provide lucrative opportunities to the market.

The global heparin market is segmented into product, application, distribution channel, and region. On the basis of product, the market is categorized into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By application, it is classified into venous thromboembolism, atrial fibrillation, coronary artery disease, and others. By distribution channel, it is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global heparin market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of heparin used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-low Molecular Weight Heparin (ULMWH)

By Application

  • Venous Thromboembolism
  • Coronary Artery Disease
  • Atrial Fibrillation
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Baxter International Inc.
  • B. Braun Holding GmbH & Co. KG
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co KGaA
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
  • Leo Pharma A/S
  • Pfizer Inc.
  • Sanofi S.A
  • Teva Pharmaceuticals
  • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020

3.5Market dynamics

    • 3.5.1.Drivers
      • 3.5.1.1.Increase in incidence of venous thromboembolism and cardiovascular disorders
      • 3.5.1.2.Rise in geriatric population
      • 3.5.1.3.Increase in usage of heparin in surgical procedures
    • 3.5.2.Restraints
      • 3.5.2.1.Side effects associated with heparin
      • 3.5.2.2.Presence of alternative anticoagulants
    • 3.5.3.Opportunities
      • 3.5.3.1.Availability of synthetic and semi-synthetic heparin mimetics
      • 3.5.3.2.R&D activities to develop heparin with improved therapeutic
    • 3.5.4.Impact analysis

3.6Covid-19 Impact analysis on heparin market

CHAPTER 4:HEPARIN MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Unfractionated Heparin
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Low Molecular Weight Heparin (LMWH)
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Ultra-low Molecular Weight Heparin (ULMWH)
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:HEPARIN MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Venous Thromboembolism
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Coronary Artery Disease
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Atrial Fibrillation
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country
  • 5.5.Others
    • 5.5.1.Market size and forecast
    • 5.5.2.Market analysis, by country

CHAPTER 6:HEPARIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Drug stores and retail pharmacies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Online pharmacies
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:HEPARIN MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. heparin market, by product
      • 7.2.2.1.2.U.S. heparin market, by application
      • 7.2.2.1.3.U.S. heparin market, by distribution channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada heparin market, by product
      • 7.2.2.2.2.Canada heparin market, by application
      • 7.2.2.2.3.Canada heparin market, by distribution channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico heparin market, by product
      • 7.2.2.3.2.Mexico heparin market, by application
      • 7.2.2.3.3.Mexico heparin market, by distribution channel
    • 7.2.3.North America market size and forecast, by product
    • 7.2.4.North America market size and forecast, by application
    • 7.2.5.North America market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany heparin market, by product
      • 7.3.2.1.2.Germany heparin market, by application
      • 7.3.2.1.3.Germany heparin market, by distribution channel
      • 7.3.2.2.France
      • 7.3.2.2.1.France heparin market, by product
      • 7.3.2.2.2.France heparin market, by application
      • 7.3.2.2.3.France heparin market, by distribution channel
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK heparin market, by product
      • 7.3.2.3.2.UK heparin market, by application
      • 7.3.2.3.3.UK heparin market, by distribution channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy heparin market, by product
      • 7.3.2.4.2.Italy heparin market, by application
      • 7.3.2.4.3.Italy heparin market, by distribution channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain heparin market, by product
      • 7.3.2.5.2.Spain heparin market, by application
      • 7.3.2.5.3.Spain heparin market, by distribution channel
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe heparin market, by product
      • 7.3.2.6.2.Rest of Europe heparin market, by application
      • 7.3.2.6.3.Rest of Europe heparin market, by distribution channel
    • 7.3.3.Europe market size and forecast, by product
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan heparin market, by product
      • 7.4.2.1.2.Japan heparin market, by application
      • 7.4.2.1.3.Japan heparin market, by distribution channel
      • 7.4.2.2.China
      • 7.4.2.2.1.China heparin market, by product
      • 7.4.2.2.2.China heparin market, by application
      • 7.4.2.2.3.China heparin market, by distribution channel
      • 7.4.2.3.India
      • 7.4.2.3.1.India heparin market, by product
      • 7.4.2.3.2.India heparin market, by application
      • 7.4.2.3.3.India heparin market, by distribution channel
      • 7.4.2.4.Australia
      • 7.4.2.4.1.Australia heparin market, by product
      • 7.4.2.4.2.Australia heparin market, by application
      • 7.4.2.4.3.Australia heparin market, by distribution channel
      • 7.4.2.5.Rest of Asia-Pacific
      • 7.4.2.5.1.Rest of Asia-Pacific heparin market, by product
      • 7.4.2.5.2.Rest of Asia-Pacific heparin market, by application
      • 7.4.2.5.3.Rest of Asia-Pacific heparin market, by distribution channel
    • 7.4.3.Asia-Pacific market size and forecast, by product
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil heparin market, by product
      • 7.5.2.1.2.Brazil heparin market, by application
      • 7.5.2.1.3.Brazil heparin market, by distribution channel
      • 7.5.2.2.South Africa
      • 7.5.2.2.1.South Africa heparin market, by product
      • 7.5.2.2.2.South Africa heparin market, by application
      • 7.5.2.2.3.South Africa heparin market, by distribution channel
      • 7.5.2.3.Saudi Arabia
      • 7.5.2.3.1.Saudi Arabia heparin market, by product
      • 7.5.2.3.2.Saudi Arabia heparin market, by application
      • 7.5.2.3.3.Saudi Arabia heparin market, by distribution channel
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA heparin market, by product
      • 7.5.2.4.2.Rest of LAMEA heparin market, by application
      • 7.5.2.4.3.Rest of LAMEA heparin market, by distribution channel
    • 7.5.3.LAMEA market size and forecast, by product
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.Baxter International Inc.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segment
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.B. Braun Holding GmbH & Co. KG
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segment
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Dr. Reddy's Laboratories Ltd.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segment
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.Fresenius SE & Co KGaA
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segment
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segment
    • 8.5.4.Product portfolio
  • 8.6.Leo Pharma A/S
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.Pfizer Inc.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.Sanofi S.A.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Teva Pharmaceuticals
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Product portfolio
    • 8.9.4.Business performance
  • 8.10.Viatris Inc.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Product portfolio
    • 8.10.4.Operating business segments
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.HEPARIN MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 02.UNFRACTIONATED HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 03.LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 04.ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 05.HEPARIN MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 06.VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 07.CORONARY ARTERY DISEASE HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 08.ATRIAL FIBRILLATION HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 09.OTHERS HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 10.HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
  • TABLE 11.HOSPITAL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 12.DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 13.ONLINE PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 14.HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 15.NORTH AMERICA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 16.U.S. HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 17.U.S. HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 18.U.S. HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 19.CANADA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 20.CANADA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 21.CANADA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 22.MEXICO HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 23.MEXICO HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 24.MEXICO HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 25.NORTH AMERICA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 26.NORTH AMERICA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 27.NORTH AMERICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 28.EUROPE HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 29.GERMANY HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 30.GERMANY HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 31.GERMANY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 32.FRANCE HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 33.FRANCE HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 34.FRANCE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 35.UK HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 36.UK HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 37.UK HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 38.ITALY HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 39.ITALY HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 40.ITALY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 41.SPAIN HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 42.SPAIN HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 43.SPAIN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 44.REST OF EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 45.REST OF EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 46.REST OF EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 47.EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 48.EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 49.EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 50.ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 51.JAPAN HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 52.JAPAN HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 53.JAPAN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 54.CHINA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 55.CHINA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 56.CHINA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 57.INDIA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 58.INDIA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 59.INDIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 60.AUSTRALIA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 61.AUSTRALIA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 62.AUSTRALIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 63.REST OF ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 64.REST OF ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 65.REST OF ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 66.ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 67.ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 68.ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 69.LAMEA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 70.BRAZIL HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 71.BRAZIL HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 72.BRAZIL HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 73.SOUTH AFRICA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 74.SOUTH AFRICA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 75.SOUTH AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 76.SAUDI ARABIA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 77.SAUDI ARABIA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 78.SAUDI ARABIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 79.REST OF LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 80.REST OF LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 81.REST OF LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 82.LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
  • TABLE 83.LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
  • TABLE 84.LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
  • TABLE 85.BAXTER: COMPANY SNAPSHOT
  • TABLE 86.BAXTER: OPERATING SEGMENTS
  • TABLE 87.BAXTER: PRODUCT PORTFOLIO
  • TABLE 88.B. BRAUN: COMPANY SNAPSHOT
  • TABLE 89.B. BRAUN: OPERATING SEGMENTS
  • TABLE 90.B.BRAUN: PRODUCT PORTFOLIO
  • TABLE 91.DR. REDDY'S LAB: COMPANY SNAPSHOT
  • TABLE 92.DR. REDDY'S LAB: OPERATING SEGMENTS
  • TABLE 93.DR. REDDY'S LAB: PRODUCT PORTFOLIO
  • TABLE 94.FRESENIUS: COMPANY SNAPSHOT
  • TABLE 95.FRESENIUS: OPERATING SEGMENTS
  • TABLE 96.FRESENIUS: PRODUCT PORTFOLIO
  • TABLE 97.HEBEI: COMPANY SNAPSHOT
  • TABLE 98.FRESENIUS: OPERATING SEGMENTS
  • TABLE 99.HEBEI: PRODUCT PORTFOLIO
  • TABLE 100.LEO: COMPANY SNAPSHOT
  • TABLE 101.LEO: OPERATING SEGMENTS
  • TABLE 102.IBM: PRODUCT PORTFOLIO
  • TABLE 103.PFIZER: COMPANY SNAPSHOT
  • TABLE 104.PFIZER: OPERATING SEGMENTS
  • TABLE 105.PFIZER: PRODUCT PORTFOLIO
  • TABLE 106.SANOFI: COMPANY SNAPSHOT
  • TABLE 107.SANOFI: OPERATING SEGMENTS
  • TABLE 108.SANOFI: PRODUCT PORTFOLIO
  • TABLE 109.ASPEN: COMPANY SNAPSHOT
  • TABLE 110.TEVA: PRODUCT PORTFOLIO
  • TABLE 111.VIATRIS: COMPANY SNAPSHOT
  • TABLE 112.VIATRIS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL HEPARIN MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 03.HIGH THREAT OF SUBSTITUTES
  • FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 05.MODERATE INTENSITY OF RIVALRY
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.IMPACT ANALYSIS
  • FIGURE 08.COMPARATIVE ANALYSIS OF UNFRACTIONATED HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 09.COMPARATIVE ANALYSIS OF LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 10.COMPARATIVE ANALYSIS OF ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 13.COMPARATIVE ANALYSIS OF ATRIAL FIBRILLATION HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 14.COMPARATIVE ANALYSIS OF OTHERS HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 18.BAXTER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 19.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 20.BAXTER: REVENUE SHARE BY REGION 2020 (%)
  • FIGURE 21.B BRAUN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.B BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 23.B BRAUN: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 24.DR. REDDY'S LAB: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 25.DR. REDDY'S LAB: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.DR. REDDY'S LAB: REVENUE SHARE BY REGION 2020 (%)
  • FIGURE 27.FRESENIUS: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 28.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.FRESENIUS: REVENUE SHARE BY REGION 2020 (%)
  • FIGURE 30.LEO: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 31.LEO: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.LEO: REVENUE SHARE BY REGION 2020 (%)
  • FIGURE 33.PFIZER: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 34.PFIZER: REVENUE SHARE BY REGION 2020 (%)
  • FIGURE 35.SANOFI: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 36.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 37.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 38.TEVA.: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 39.TEVA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 40.VIATRIS: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 41.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)